NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.

Workspace · Cancer algorithms · Non-Hodgkin lymphoma (heme stub)

Non-Hodgkin lymphoma (heme stub)

Non-Hodgkin lymphoma (heme stub) · 79,320 new · 19,970 deaths (ACS 2026) · mortality 4.8 per 100k · 5-yr RS 74.3% (SEER)

Mortality 4.8 per 100k (SEER / ACS common-sites). Never an artboard percent.

Lifetime ≈ 2.0% (SEER Stat Facts). 872,940 people living with NHL in 2023. NHL pin only — leukemia and myeloma are not this row. Not a Hodgkin incidence model.

872,940 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.

Median age at diagnosis 68 · at death 76 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.

Incidence men 22.4 / women 15.6 per 100k · mortality men 6.2 / women 3.6 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.

Most often diagnosed among people aged 65–74. Deaths highest among people aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.

New cases falling 0.6% each year (2014–2023). Death rates falling 2.4% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.

Highest new-case rate: Non-Hispanic White men 24.2 per 100k. Highest death rate: Non-Hispanic White men 6.6 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

Race/ethnicity rates per 100k (SEER Stat Facts)

SEER Stat Facts race and ethnicity incidence and mortality per 100k
Group	Inc. men	Inc. women	Deaths men	Deaths women
Hispanic	20.5	15.8	5.2	3.4
Non-Hispanic American Indian/Alaska Native	17.6	12.6	5.7	3.2
Non-Hispanic Asian/Pacific Islander	16.7	11.7	4.4	2.7
Non-Hispanic Black	16.9	11.9	4.6	2.6
Non-Hispanic White	24.2	16.5	6.6	3.8

Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.

USPSTF screening pointer

No USPSTF population-screening recommendation is cited for this stub.

ACS / SEER pin only. Not encoded. Not a screening recommendation.

ACS early-detection pointer

ACS 2024 · People without NHL symptoms · ACS (2024): there are no widely recommended screening tests for non-Hodgkin lymphoma. Screening here means looking for disease in people who have no symptoms. Complementary to the cited NHL pin. Not a population lymphoma-screen engine.

Cited ACS statement only. Not a screening engine. ACS-nhl-detect

Surveillance pointer

COG-LTFU cited · cited only · COG Long-Term Follow-Up class is cited for lymphoma survivors. NHL follow-up months are not encoded.

Named public source only. Not a personal follow-up calendar. COG-LTFU

Surveillance pointer

ACS-nhl-follow 2024 · cited only · ACS living-as-a-survivor page names regular follow-up visits, usually every few months for the first year or so and then less often, because lymphoma can come back many years later. Those months are not encoded. Complementary to the COG LTFU class pointer. No invented relapse percent. Not a PET/CT calendar engine.

Named public source only. Not a personal follow-up calendar. ACS-nhl-follow

Surveillance pointer

ACS-nhl-follow 2024 · cited only · ACS living-as-a-survivor page names yearly breast MRI plus mammogram and clinical exam beginning at age 30 after chest radiation, then says most experts do not recommend any additional testing to look for second cancers. Those ACS breast-imaging months are not encoded. Complementary to the COG LTFU class pointer and the ACS living-as row. Not a second-primary screening engine.

Named public source only. Not a personal follow-up calendar. ACS-nhl-follow

Surveillance pointer

ACS-long-term-effects 2025 · cited only · ACS long-term page names later heart problems after anthracyclines or chest radiation and lung problems after bleomycin or chest radiation. AML after chemo and breast cancer after chest radiation are named as examples. Those names are not encoded. Complementary to the COG LTFU class pointer and the ACS living-as / second-cancer rows. Not an AML, PET/CT, or Lung-RADS engine.

Named public source only. Not a personal follow-up calendar. ACS-long-term-effects

Surveillance pointer

ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a yearly thyroid exam after head, neck, or throat radiation, lung function tests after some chemo or transplant, echoes after cardiotoxic chemo, and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Complementary to the lymphoma/myeloma printout. Official Stage I percent-of-cases cells are not restated. Not an AML, PET/CT, or Lung-RADS engine.

Named public source only. Not a personal follow-up calendar. ACS-follow-up-care

Toxicity pointer

ASCO-survivorship cited · cited only · ASCO survivorship / cardiomyopathy materials are cited. NHL late-effect months are not encoded.

Named public source only. Flags are not dose reconstruction. ASCO-survivorship

Toxicity pointer

ACS-nhl-follow 2024 · empty on purpose · ACS living-as-a-survivor page names treatment side effects that might last a long time or show up years later. Those late effects are not encoded. Complementary to the ASCO survivorship pointer. No dose reconstruction.

Named public source only. Flags are not dose reconstruction. ACS-nhl-follow

Toxicity pointer

ACS-nhl-follow 2024 · empty on purpose · ACS living-as-a-survivor page names later cancers after non-Hodgkin lymphoma treatment. Those second-cancer risks are not encoded. Complementary to the COG / ASCO first rows. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-nhl-follow

Toxicity pointer

ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later heart problems after anthracyclines or chest radiation, lung problems after bleomycin, and example second cancers after chemo or chest radiation. Those late effects are not encoded. Complementary to the COG / ASCO first rows. Not an AML engine. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-long-term-effects

Toxicity pointer

ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a yearly thyroid exam, lung function tests, echoes after cardiotoxic chemo, and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Complementary to the lymphoma/myeloma printout. Empty on purpose.

Named public source only. Flags are not dose reconstruction. ACS-follow-up-care

Late toxicity printout

Late toxicity printout — Lymphoma / myeloma fields

Acute: ACS names fatigue, field skin change, sore throat, nausea, and low blood counts. Late: heart and lung problems after chest-field RT or named cardiotoxic or lung-toxic drugs, thyroid problems after neck-field RT, breast-imaging after chest RT, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, fertility effects, sexuality changes, neuropathy after chemo, and cognitive change after chemo. Monitor: COG / ASCO echo flags; yearly thyroid exam; lung function tests after some chemo or transplant; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; numbness or tingling after chemo; memory, thinking, or focus change after chemo. Those names are not encoded. Hodgkin stays Ann Arbor. Official Stage I percent-of-cases cells are not restated. Anthracycline and bleomycin stay unnamed as myeloma-specific. Not an AML or PET/CT engine.

Anthracycline and bleomycin stay unnamed as myeloma-specific.

Questions to ask

ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.

ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.

ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.

Treatment summary and care plan

ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.

How late effects are managed

ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.

ACS long-term late names

Heart problems after anthracyclines or chest RT
Lung problems after bleomycin or chest RT
Second cancers after chemo or chest RT
Cancer-related fatigue that lasts
Joint or muscle pain after some treatments
Mental health and distress after treatment
Bowel or bladder problems after abdomen or pelvis treatment
Hearing loss after high-dose platinum chemo
Cavities and tooth loss after chemo
Peripheral neuropathy after chemo
Cognitive impairment after brain RT or chemo
Heart problems after some cardiotoxic treatments
Low thyroid hormones after head or neck radiation
Lung problems after bleomycin, busulfan, or chest RT
Fertility after pelvis, belly, or spine RT
Sexuality after cancer treatment

ACS follow-up tests named here

Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30

Named conditions to monitor

Anthracycline echo and chest-RT flags
Breast imaging after chest RT before age 30
Second-cancer testing
Cardiologist or pulmonologist after named cardiotoxic or lung-toxic treatment
Cancer-related fatigue or sleep problems that last
Joint or muscle pain after chemo, steroids, or hormone therapy
Anxiety, depression, or fear of recurrence after treatment
Bowel or bladder change after abdomen or pelvis treatment
Hearing change after high-dose platinum chemo
Cavity risk after chemo
Numbness or tingling in the feet or hands after chemo
New or worsening memory, thinking, or focus
New heart symptoms years after cardiotoxic treatment
Fatigue, hair loss, or feeling colder after head or neck radiation
Cough, shortness of breath, or wheezing after lung-toxic treatment
Fertility after pelvis, belly, or spine treatment
Sexuality or body-image change after treatment
Second-cancer awareness after radiation or chemo
Ask which late-effect tests belong on the follow-up plan

Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS / COG / ASCO field names only. Complementary ACS long-term page is named, not encoded. Hodgkin stays Ann Arbor, not localized/regional/distant. No dose reconstruction. Official Stage I percent-of-cases cells are not restated.

Open Lymphoma / myeloma fields printout →

NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.

algo-stub-heme · stub · none · v2-stub-heme

NHL Ann Arbor — not localized / regional / distant

I 87.6% · II 79.7% · III 74% · IV 63.6% · all 74.3%

Non-Hodgkin lymphoma Ann Arbor I–IV. Not localized / regional / distant. Separate from Hodgkin.

NHL percent of cases by Ann Arbor stage

I 21% · II 15% · III 17% · IV 37% · Unknown 10%

Ann Arbor percent of cases — not 5-year relative survival. Not localized / regional / distant. Separate from Hodgkin.

lifetime
Non-Hodgkin lymphoma birth-to-death
≈ 2.0%

Screening · Surveillance · Toxicity on four golden fixtures

Rio · Plan — survivor

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF NHL population-screening rec cited
Cited ACS 2024 NHL no-screen note. Ann Arbor stage survival is cited; it is not a screening interval.
not encoded
surveillance
COG LTFU class cited — NHL months not encoded
Cited lymphoma-survivor class, plus the complementary ACS living-as page. No invented relapse percent.
not encoded
toxicity
ASCO survivorship cited — NHL late-effect months not encoded
Named source only. No dose reconstruction.
not encoded

Noah · Plan — skin cancer

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF NHL population-screening rec cited
Cited ACS 2024 NHL no-screen note. Ann Arbor stage survival is cited; it is not a screening interval.
not encoded
surveillance
COG LTFU class cited — NHL months not encoded
Cited lymphoma-survivor class, plus the complementary ACS living-as page. No invented relapse percent.
not encoded
toxicity
ASCO survivorship cited — NHL late-effect months not encoded
Named source only. No dose reconstruction.
not encoded

Walter · S1 prostate

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF NHL population-screening rec cited
Cited ACS 2024 NHL no-screen note. Ann Arbor stage survival is cited; it is not a screening interval.
not encoded
surveillance
COG LTFU class cited — NHL months not encoded
Cited lymphoma-survivor class, plus the complementary ACS living-as page. No invented relapse percent.
not encoded
toxicity
ASCO survivorship cited — NHL late-effect months not encoded
Named source only. No dose reconstruction.
not encoded

Priya · average-risk

not computed — v2 stub

Cited ACS/SEER population pin only

screening
No USPSTF NHL population-screening rec cited
Cited ACS 2024 NHL no-screen note. Ann Arbor stage survival is cited; it is not a screening interval.
not encoded
surveillance
COG LTFU class cited — NHL months not encoded
Cited lymphoma-survivor class, plus the complementary ACS living-as page. No invented relapse percent.
not encoded
toxicity
ASCO survivorship cited — NHL late-effect months not encoded
Named source only. No dose reconstruction.
not encoded

Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.

All cancers →Screening →Surveillance →Toxicity →